Carol, I found a few more articles with info about treating CAH. Again, sorry I can't fax the whole articles. I hope I can give you enough info to find them on your own. I also hope nothing I relay is misleading. I know you can pull something out of context and make it say just about anything. I am trying hard not to do that, but it would be good if you could read the whole articles. 1) From a booklet put out by Johns Hopkins Hospital. (This is a great little booklet. It is free and can be ordered by calling (410) 614-5576 or visiting the web site http://www.med.jhu.edu/pedendo/index.html) Someone from this board, sorry can't remember who, posted about this booklet. Her beautiful little child is on the front cover) "Cortisol Treatment. P.8 The oral preparation available includes Cortef tablets (5, 10, and 20 mg) and Cortef suspension (2 mg of cortisol per 1ml). Because gastric acid destroys some of the oral cortisol, the treatment dose must be about twice that of normal production (15 to 30 mg per square meter of body surface area, every 24 hours)" 2) From an article (found on the web at http://www.medhelp.org/www/nadf5.htm) from NADF titled New Developments in the Treatment and Diagnosis of Congenital Adrenal Hyperplasia. "Standard CAH treatment: . . . A particularly important factor in determining final height in CAH patients is the amount of steroids given as treatment in the first 2 years of life. Doctors are now advocating more modest treatment doses to preserve height potential." 3) From an article in JAMA, April 2, 1997, Volume 277, No. 13 titled New Approaches to the Treatment of Congenital Adrenal Hyperplasia by Merke and Cutler. " Current Treatment . . . There are two extremes that the clinician must try to avoid. The first is the untreated or undertreated state. . . The second extreme is overtreatment. Giving enough hyrdrocortisone to supress androgens to normal or near-normal levels often results in treatment-induced-hypercortisolism. Treatment with supraphysiologic doses of glucocorticoid leads to a cushingoid appearance, with obesity and short stature. Cortisol in excess has direct growth-inhibiting effect on the chondrocyte, which can lead to short stature not from early epiphyseal fusion but from the growth inhibiting effects of cortisol. . . . ":